Importantly, we demonstrated the therapeutic value of SLC25A21 because its overexpression sensitized KRAS-mutant CRC cells to CTX in vitro by decreasing the level of mitochondrial α-KG, a raw material for GTP production. This evidence concerns the gene KRAS and colorectal carcinoma.